Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L Feldman, Brian K Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J M Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M Reis, Marco Paulli, Izidore S Lossos, James R Cerhan, Stefano Luminari
BACKGROUND: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. METHODS: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment...
June 2024: EClinicalMedicine